BiotechTube
Adipo Therapeutics

Adipo Therapeutics

Cambridge, United States· Est.
adipotherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Adipo Therapeutics is a private, preclinical-stage biotech founded in 2018, targeting obesity through a first-in-class mechanism. The company's platform utilizes nanotechnology to deliver Notch inhibitors, aiming to 'brown' white fat and increase resting metabolic rate, as demonstrated in preclinical and ex-vivo human tissue studies. Leveraging talent from Indiana's academic and pharmaceutical ecosystem, Adipo is positioning itself to address the massive unmet need in the metabolic disease market with a therapy focused on energy expenditure rather than appetite suppression.

ObesityMetabolic Disease

Technology Platform

Notch-inhibiting nanoparticles designed to promote the browning of white adipose tissue to increase energy expenditure.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive and growing global obesity epidemic presents a multi-billion dollar market with high unmet need for therapies with novel mechanisms.
Adipo's energy-expenditure approach could be complementary to existing appetite-suppressing drugs, offering combination potential.
Positive human data could attract partnership interest from large pharmaceutical companies active in metabolic diseases.

Risk Factors

High scientific risk in translating a novel nanoparticle-based Notch inhibition approach from preclinical models to safe and effective human therapy.
Intense competition in the obesity drug market from well-funded companies with advanced clinical programs.
Uncertain regulatory pathway and eventual reimbursement landscape for a new class of obesity therapeutics.

Competitive Landscape

Adipo operates in the highly competitive obesity therapeutics market, currently dominated by GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from Novo Nordisk and Eli Lilly. Its primary differentiation is its mechanism of action focused on increasing energy expenditure rather than reducing appetite. Other companies are exploring metabolic rate modulation, but Adipo's specific approach via Notch-inhibiting nanoparticles appears to be first-in-class.

More companies in Small Molecule Drugs →More companies in United States →